Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
- Conditions
- Acute T Lymphoblastic Leukemia (T-ALL)Acute B Lymphoblastic Leukemia (B-ALL)
- Interventions
- Drug: injection of BEP 800Other: Control
- Registration Number
- NCT04437420
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Brief Summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 44
- Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
- Patient over 80 years of age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description T-ALL injection of BEP 800 - T-ALL Control - B-ALL injection of BEP 800 - B-ALL Control -
- Primary Outcome Measures
Name Time Method Viability on primary ALL samples 2 years The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.
- Secondary Outcome Measures
Name Time Method Effect on SRC phosphorylation 2 years The effect of BEP-800 on T-ALL and B-ALL will be evaluated by flow cytometry by measuring HSP90 and SRC (phosphorylated), by intracellular labeling after permeabilization of the cells, 18 hours after treatment with BEP-800.
Trial Locations
- Locations (1)
Chu Dijon Bourgogne
🇫🇷Dijon, France